Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.72 |
| ▸ | CMA1 | P23946 | 2/20 | 0.72 |
| ▸ | TDP2 | O95551 | 2/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29737119 | 0.91 | AHR (0.62) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL7715803 | 0.87 | PGR (0.62) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL29584808 | 0.84 | AHR (1.00) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL19982 | 0.84 | AHR (1.00) | AHRCMA1TDP2IDO1PDE3B | |
| Tert-Butyl Formate SCHEMBL27780535 | 0.83 | AHR (0.53) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL28379766 | 0.83 | BRD4 (0.56) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL30855391 | 0.83 | BRD4 (0.56) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL8131472 | 0.82 | AHR (0.96) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL1233125 | 0.82 | AHR (0.96) | AHRCMA1TDP2IDO1PDE3B | |
| SCHEMBL99208 | 0.82 | MAOA (0.56) | AHRCMA1TDP2IDO1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 894 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | claimed |
| CN-116082213-A | Preparation method of 5-cyanoindole | 苏州永健生物医药有限公司 | 2023-05-09 | — | — | CN | claimed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | claimed |
| JP-2002540096-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-6469181-B1 | PREPARING 2-OXINDOLES AND N-HYROXY-2- OXINDOLES VIA REDUCTION OF 2-NITROARYLMALONATE DIESTERS WITHOUT ISOLATION OF INTERMEDIATES | CATALYTICA, INC. | 2002-10-22 | — | — | US | claimed |
| CN-1078590-C | Process for preparing 2-oxindoles and N-hydroxy-2-oxindoles | CATALYTICA INC (US) | 2002-01-30 | — | — | CN | claimed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| EP-0809631-A4 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA INC (US) | 1998-07-08 | — | — | EP | claimed |
| CN-1177347-A | Process for preparing 2 -oxindoles and N -hydroxy -2 -oxindoles | CATALYTICA INC (US) | 1998-03-25 | — | — | CN | claimed |
| EP-0809631-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1996023770-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1996-08-08 | — | — | WO | claimed |
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | UCB Biopharma SRL (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4081295-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-3984405-A | PYRIDO(3,2-B)(1,4)OXAZIN-3(4H)-ONES | E. R. SQUIBB & SONS, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | HRH2, HRH4, HRH1 | AHR 525/4885CMA1 12/4885TDP2 4793/4885 |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | AHR 1643/4885CMA1 2819/4885TDP2 1204/4885 |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | AHR 33/4885CMA1 1854/4885TDP2 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.